Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Aptevo Therapeutics Inc.APVO · Entity 8337 | Director | December 03, 2021 | December 08, 2021 |
| Emergent BioSolutions Inc.EBS · Entity 5902 | Director | December 03, 2021 | December 08, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Aptevo Therapeutics Inc.
Report date December 03, 2021 · Filed December 08, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 107,807 |
Reported balance
After 2021-12-03 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2021-12-03 · Other · Acquired 107,807 · Balance 107,807 F1: On December 3, 2021, each of Intervac L.L.C., a Maryland limited liability company ("Intervac"), and BioVac, L.L.C., a Maryland limited liability company ("BioVac"), effected a pro-rata liquidating distribution to their respective members of shares of the Issuer's common stock for no consideration (the "Distribution"). In prior reports filed by the reporting person pursuant to Section 16, the reporting person reported indirect beneficial ownership over shares of the Issuer's common stock held by Intervac and BioVac. After giving effect to the Distribution, the reporting person no longer has beneficial ownership over 5,880 shares of the Issuer's common stock that was previously reported as beneficially owned by BioVac. F2: Held by the Yahia Fuad El-Hibri Revocable Trust, for which the reporting person serves as the Trustee. Comprised of (i) 59,253 shares of the Issuer's common stock previously reported as beneficially owned by Intervac and (ii) 48,554 shares of the Issuer's common stock previously reported as beneficially owned by BioVac. The reporting person expressly disclaims beneficial ownership of any shares of the Issuer's common stock owned by the Yahia Fuad El-Hibri Revocable Trust except to the extent of his pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 9,819 |
Reported balance
After 2021-12-03 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2021-12-03 · Other · Acquired 9,819 · Balance 9,819 F1: On December 3, 2021, each of Intervac L.L.C., a Maryland limited liability company ("Intervac"), and BioVac, L.L.C., a Maryland limited liability company ("BioVac"), effected a pro-rata liquidating distribution to their respective members of shares of the Issuer's common stock for no consideration (the "Distribution"). In prior reports filed by the reporting person pursuant to Section 16, the reporting person reported indirect beneficial ownership over shares of the Issuer's common stock held by Intervac and BioVac. After giving effect to the Distribution, the reporting person no longer has beneficial ownership over 5,880 shares of the Issuer's common stock that was previously reported as beneficially owned by BioVac. F3: Held by the El-Hibri Family Trust, for which the reporting person's wife serves as the Trustee. The reporting person expressly disclaims beneficial ownership of any shares of the Issuer's common stock owned by the El-Hibri Family Trust except to the extent of his pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 7,373 |
Reported balance
After 2021-12-03 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2021-12-03 · Other · Acquired 7,373 · Balance 7,373 F1: On December 3, 2021, each of Intervac L.L.C., a Maryland limited liability company ("Intervac"), and BioVac, L.L.C., a Maryland limited liability company ("BioVac"), effected a pro-rata liquidating distribution to their respective members of shares of the Issuer's common stock for no consideration (the "Distribution"). In prior reports filed by the reporting person pursuant to Section 16, the reporting person reported indirect beneficial ownership over shares of the Issuer's common stock held by Intervac and BioVac. After giving effect to the Distribution, the reporting person no longer has beneficial ownership over 5,880 shares of the Issuer's common stock that was previously reported as beneficially owned by BioVac. F4: Held by the El-Hibri Decedents Trust, for which the reporting person serves as the Trustee. The reporting person expressly disclaims beneficial ownership of any shares of the Issuer's common stock owned by the El-Hibri Decedents Trust except to the extent of his pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | Direct | 80,324 |
Reported balance
Holding disclosure · report date 2021-12-03 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 80,324 |
Filing footnotes · ownership attribution and instrument terms
F1: On December 3, 2021, each of Intervac L.L.C., a Maryland limited liability company ("Intervac"), and BioVac, L.L.C., a Maryland limited liability company ("BioVac"), effected a pro-rata liquidating distribution to their respective members of shares of the Issuer's common stock for no consideration (the "Distribution"). In prior reports filed by the reporting person pursuant to Section 16, the reporting person reported indirect beneficial ownership over shares of the Issuer's common stock held by Intervac and BioVac. After giving effect to the Distribution, the reporting person no longer has beneficial ownership over 5,880 shares of the Issuer's common stock that was previously reported as beneficially owned by BioVac.
F2: Held by the Yahia Fuad El-Hibri Revocable Trust, for which the reporting person serves as the Trustee. Comprised of (i) 59,253 shares of the Issuer's common stock previously reported as beneficially owned by Intervac and (ii) 48,554 shares of the Issuer's common stock previously reported as beneficially owned by BioVac. The reporting person expressly disclaims beneficial ownership of any shares of the Issuer's common stock owned by the Yahia Fuad El-Hibri Revocable Trust except to the extent of his pecuniary interest therein.
F3: Held by the El-Hibri Family Trust, for which the reporting person's wife serves as the Trustee. The reporting person expressly disclaims beneficial ownership of any shares of the Issuer's common stock owned by the El-Hibri Family Trust except to the extent of his pecuniary interest therein.
F4: Held by the El-Hibri Decedents Trust, for which the reporting person serves as the Trustee. The reporting person expressly disclaims beneficial ownership of any shares of the Issuer's common stock owned by the El-Hibri Decedents Trust except to the extent of his pecuniary interest therein.
Emergent BioSolutions Inc.
Report date December 03, 2021 · Filed December 08, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 3,018,644 |
Reported balance
After 2021-12-03 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2021-12-03 · Other · Acquired 3,018,644 · Balance 3,018,644 F1: On December 3, 2021, each of Intervac L.L.C., a Maryland limited liability company ("Intervac"), and BioVac, L.L.C., a Maryland limited liability company ("BioVac"), effected a pro-rata liquidating distribution to their respective members of shares of the Issuer's common stock for no consideration (the "Distribution"). In prior reports filed by the reporting person pursuant to Section 16, the reporting person reported indirect beneficial ownership over shares of the Issuer's common stock held by Intervac and BioVac. After giving effect to the Distribution, the reporting person no longer has beneficial ownership over 164,610 shares of the Issuer's common stock that was previously reported as beneficially owned by BioVac. F2: Held by the Yahia Fuad El-Hibri Revocable Trust, for which the reporting person serves as the Trustee. Comprised of (i) 1,659,099 shares of the Issuer's common stock previously reported as beneficially owned by Intervac and (ii) 1,359,545 shares of the Issuer's common stock previously reported as beneficially owned by BioVac. The reporting person expressly disclaims beneficial ownership of any shares of the Issuer's common stock owned by the Yahia Fuad El-Hibri Revocable Trust except to the extent of his pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 274,930 |
Reported balance
After 2021-12-03 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2021-12-03 · Other · Acquired 274,930 · Balance 274,930 F1: On December 3, 2021, each of Intervac L.L.C., a Maryland limited liability company ("Intervac"), and BioVac, L.L.C., a Maryland limited liability company ("BioVac"), effected a pro-rata liquidating distribution to their respective members of shares of the Issuer's common stock for no consideration (the "Distribution"). In prior reports filed by the reporting person pursuant to Section 16, the reporting person reported indirect beneficial ownership over shares of the Issuer's common stock held by Intervac and BioVac. After giving effect to the Distribution, the reporting person no longer has beneficial ownership over 164,610 shares of the Issuer's common stock that was previously reported as beneficially owned by BioVac. F3: Held by the El-Hibri Family Trust, for which the reporting person's wife serves as the Trustee. The reporting person expressly disclaims beneficial ownership of any shares of the Issuer's common stock owned by the El Hibri Family Trust except to the extent of his pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 206,434 |
Reported balance
After 2021-12-03 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2021-12-03 · Other · Acquired 206,434 · Balance 206,434 F1: On December 3, 2021, each of Intervac L.L.C., a Maryland limited liability company ("Intervac"), and BioVac, L.L.C., a Maryland limited liability company ("BioVac"), effected a pro-rata liquidating distribution to their respective members of shares of the Issuer's common stock for no consideration (the "Distribution"). In prior reports filed by the reporting person pursuant to Section 16, the reporting person reported indirect beneficial ownership over shares of the Issuer's common stock held by Intervac and BioVac. After giving effect to the Distribution, the reporting person no longer has beneficial ownership over 164,610 shares of the Issuer's common stock that was previously reported as beneficially owned by BioVac. F4: Held by the El-Hibri Decedents Trust, for which the reporting person serves as the Trustee. The reporting person expressly disclaims beneficial ownership of any shares of the Issuer's common stock owned by the El-Hibri Decendents Trust except to the extent of his pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | Direct | 1,136,971 |
Reported balance
Holding disclosure · report date 2021-12-03 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 1,136,971 |
Filing footnotes · ownership attribution and instrument terms
F1: On December 3, 2021, each of Intervac L.L.C., a Maryland limited liability company ("Intervac"), and BioVac, L.L.C., a Maryland limited liability company ("BioVac"), effected a pro-rata liquidating distribution to their respective members of shares of the Issuer's common stock for no consideration (the "Distribution"). In prior reports filed by the reporting person pursuant to Section 16, the reporting person reported indirect beneficial ownership over shares of the Issuer's common stock held by Intervac and BioVac. After giving effect to the Distribution, the reporting person no longer has beneficial ownership over 164,610 shares of the Issuer's common stock that was previously reported as beneficially owned by BioVac.
F2: Held by the Yahia Fuad El-Hibri Revocable Trust, for which the reporting person serves as the Trustee. Comprised of (i) 1,659,099 shares of the Issuer's common stock previously reported as beneficially owned by Intervac and (ii) 1,359,545 shares of the Issuer's common stock previously reported as beneficially owned by BioVac. The reporting person expressly disclaims beneficial ownership of any shares of the Issuer's common stock owned by the Yahia Fuad El-Hibri Revocable Trust except to the extent of his pecuniary interest therein.
F3: Held by the El-Hibri Family Trust, for which the reporting person's wife serves as the Trustee. The reporting person expressly disclaims beneficial ownership of any shares of the Issuer's common stock owned by the El Hibri Family Trust except to the extent of his pecuniary interest therein.
F4: Held by the El-Hibri Decedents Trust, for which the reporting person serves as the Trustee. The reporting person expressly disclaims beneficial ownership of any shares of the Issuer's common stock owned by the El-Hibri Decendents Trust except to the extent of his pecuniary interest therein.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 14, 2017 Filed Nov 17, 2017 22:46 UTC Amendment | Emergent BioSolutions Inc. EBS · Entity 5902 | Exercise / conversionEmployee Stock Options (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $22.03 | $0.00 |
DisclosureSEC source: 0000899243-17-026845 · doc4a.xml · derivative · entry 8 El-Hibri Fuad · CIK 0001380185 · Director · Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,983 Underlying: Common Stock · 20,000 shares Expires 2018-03-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The options vested in three equal installments on March 14, 2012, March 14, 2013 and March 14, 2014. Read SEC document |
| November 14, 2017 Filed Nov 17, 2017 22:46 UTC Amendment | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 20,000 | $40.05 | $801,000.00 |
DisclosureSEC source: 0000899243-17-026845 · doc4a.xml · nonDerivative · entry 4 El-Hibri Fuad · CIK 0001380185 · Director · Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,530,216 F1 · kind: All sales listed on this Form 4 were made by Mr. El-Hibri pursuant to a trading plan adopted on February 28, 2017 that is intended to comply with Rule 10b5-1(c) under the Exchange Act. F3 · price: The selling price of $40.05 is reflective of the weighted average sale price of all transactions reported on this line. The prices for the transactions reported on this line range from $39.81 to $40.55, inclusive. Mr. El-Hibri undertakes to provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| November 14, 2017 Filed Nov 17, 2017 22:46 UTC Amendment | Emergent BioSolutions Inc. EBS · Entity 5902 | Exercise / conversionCommon Stock | 20,000 | $22.03 | $440,600.00 |
DisclosureSEC source: 0000899243-17-026845 · doc4a.xml · nonDerivative · entry 3 El-Hibri Fuad · CIK 0001380185 · Director · Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,550,216 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All sales listed on this Form 4 were made by Mr. El-Hibri pursuant to a trading plan adopted on February 28, 2017 that is intended to comply with Rule 10b5-1(c) under the Exchange Act. Read SEC document |
| November 13, 2017 Filed Nov 15, 2017 21:37 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 20,000 | $40.69 | $813,800.00 |
DisclosureSEC source: 0000899243-17-026353 · doc4.xml · nonDerivative · entry 1 El-Hibri Fuad · CIK 0001380185 · Director · Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,510,216 F1 · kind: All sales listed on this Form 4 were made by Mr. El-Hibri pursuant to a trading plan adopted on February 28, 2017 that is intended to comply with Rule 10b5-1(c) under the Exchange Act. F2 · price: The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.26 to $40.98. Read SEC document |
| November 13, 2017 Filed Nov 17, 2017 22:46 UTC Amendment | Emergent BioSolutions Inc. EBS · Entity 5902 | Exercise / conversionEmployee Stock Options (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $22.03 | $0.00 |
DisclosureSEC source: 0000899243-17-026845 · doc4a.xml · derivative · entry 7 El-Hibri Fuad · CIK 0001380185 · Director · Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,983 Underlying: Common Stock · 20,000 shares Expires 2018-03-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The options vested in three equal installments on March 14, 2012, March 14, 2013 and March 14, 2014. Read SEC document |
| November 13, 2017 Filed Nov 17, 2017 22:46 UTC Amendment | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 20,000 | $40.69 | $813,800.00 |
DisclosureSEC source: 0000899243-17-026845 · doc4a.xml · nonDerivative · entry 2 El-Hibri Fuad · CIK 0001380185 · Director · Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,530,216 F1 · kind: All sales listed on this Form 4 were made by Mr. El-Hibri pursuant to a trading plan adopted on February 28, 2017 that is intended to comply with Rule 10b5-1(c) under the Exchange Act. F2 · price: The selling price of $40.69 is reflective of the weighted average sale price of all transactions reported on this line. The prices for the transactions reported on this line range from $40.26 to $40.98, inclusive. Mr. El-Hibri undertakes to provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| November 13, 2017 Filed Nov 17, 2017 22:46 UTC Amendment | Emergent BioSolutions Inc. EBS · Entity 5902 | Exercise / conversionCommon Stock | 20,000 | $22.03 | $440,600.00 |
DisclosureSEC source: 0000899243-17-026845 · doc4a.xml · nonDerivative · entry 1 El-Hibri Fuad · CIK 0001380185 · Director · Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,550,216 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All sales listed on this Form 4 were made by Mr. El-Hibri pursuant to a trading plan adopted on February 28, 2017 that is intended to comply with Rule 10b5-1(c) under the Exchange Act. Read SEC document |
| September 29, 2017 Filed Sep 29, 2017 22:04 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 25,000 | $40.50 | $1,012,500.00 |
DisclosureSEC source: 0000899243-17-022995 · doc4.xml · nonDerivative · entry 2 El-Hibri Fuad · CIK 0001380185 · Director · Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,530,216 F1 · kind: All sales listed on this Form 4 were made by Mr. El-Hibri pursuant to a trading plan adopted on February 28, 2017 that is intended to comply with Rule 10b5-1(c) under the Exchange Act. Read SEC document |
| September 27, 2017 Filed Sep 29, 2017 22:04 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 25,000 | $39.50 | $987,500.00 |
DisclosureSEC source: 0000899243-17-022995 · doc4.xml · nonDerivative · entry 1 El-Hibri Fuad · CIK 0001380185 · Director · Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,555,216 F1 · kind: All sales listed on this Form 4 were made by Mr. El-Hibri pursuant to a trading plan adopted on February 28, 2017 that is intended to comply with Rule 10b5-1(c) under the Exchange Act. Read SEC document |
| September 14, 2017 Filed Sep 14, 2017 21:27 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 23,547 | $38.50 | $906,559.50 |
DisclosureSEC source: 0000899243-17-022088 · doc4.xml · nonDerivative · entry 2 El-Hibri Fuad · CIK 0001380185 · Director · Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,580,216 F1 · kind: All sales listed on this Form 4 were made by Mr. El-Hibri pursuant to a trading plan adopted on February 28, 2017 that is intended to comply with Rule 10b5-1(c) under the Exchange Act. Read SEC document |
| September 12, 2017 Filed Sep 14, 2017 21:27 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 1,453 | $38.50 | $55,940.50 |
DisclosureSEC source: 0000899243-17-022088 · doc4.xml · nonDerivative · entry 1 El-Hibri Fuad · CIK 0001380185 · Director · Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,603,763 F1 · kind: All sales listed on this Form 4 were made by Mr. El-Hibri pursuant to a trading plan adopted on February 28, 2017 that is intended to comply with Rule 10b5-1(c) under the Exchange Act. Read SEC document |
| September 07, 2017 Filed Sep 8, 2017 18:31 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 16,439 | $37.50 | $616,462.50 |
DisclosureSEC source: 0000899243-17-021646 · doc4.xml · nonDerivative · entry 1 El-Hibri Fuad · CIK 0001380185 · Director · Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,605,216 F1 · kind: All sales listed on this Form 4 were made by Mr. El-Hibri pursuant to a trading plan adopted on February 28, 2017 that is intended to comply with Rule 10b5-1(c) under the Exchange Act. Read SEC document |
| September 05, 2017 Filed Sep 6, 2017 22:21 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 3,100 | $37.50 | $116,250.00 |
DisclosureSEC source: 0000899243-17-021545 · doc4.xml · nonDerivative · entry 1 El-Hibri Fuad · CIK 0001380185 · Director · Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,621,655 F1 · kind: All sales listed on this Form 4 were made by Mr. El-Hibri pursuant to a trading plan adopted on February 28, 2017 that is intended to comply with Rule 10b5-1(c) under the Exchange Act. Read SEC document |
| August 31, 2017 Filed Sep 1, 2017 23:31 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 5,461 | $37.50 | $204,787.50 |
DisclosureSEC source: 0000899243-17-021371 · doc4.xml · nonDerivative · entry 1 El-Hibri Fuad · CIK 0001380185 · Director · Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,624,755 F1 · kind: All sales listed on this Form 4 were made by Mr. El-Hibri pursuant to a trading plan adopted on February 28, 2017 that is intended to comply with Rule 10b5-1(c) under the Exchange Act. Read SEC document |
| July 27, 2017 Filed Jul 28, 2017 18:12 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 25,000 | $36.50 | $912,500.00 |
DisclosureSEC source: 0000899243-17-019269 · doc4.xml · nonDerivative · entry 1 El-Hibri Fuad · CIK 0001380185 · Director · Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,630,216 F1 · kind: All sales listed on this Form 4 were made by the Reporting Person pursuant to a trading plan adopted on February 28, 2017 that is intended to comply with Rule 10b5-1(c) under the Exchange Act. Read SEC document |
| July 20, 2017 Filed Jul 21, 2017 21:27 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 25,000 | $35.50 | $887,500.00 |
DisclosureSEC source: 0000899243-17-018715 · doc4.xml · nonDerivative · entry 1 El-Hibri Fuad · CIK 0001380185 · Director · Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,655,216 F1 · kind: All sales listed on this Form 4 were made by the Reporting Person pursuant to a trading plan adopted on February 28, 2017 that is intended to comply with Rule 10b5-1(c) under the Exchange Act. Read SEC document |
| June 01, 2017 Filed Jun 2, 2017 01:36 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | GrantEmployee Stock Option (right to buy) · Derivative | 12,500 | $0.00 Strike: $2.15 | $0.00 |
DisclosureSEC source: 0001019056-17-000542 · elhibri_4.xml · derivative · entry 1 El-Hibri Fuad · CIK 0001380185 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2027-05-31 F1 · derivative.exercise_date: The option vests in three equal annual installments beginning on June 1, 2018. Read SEC document |
| March 10, 2017 Filed Mar 10, 2017 22:48 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Exercise / conversionRestrictive Stock Units · Derivative | 20,554 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-007180 · doc4.xml · derivative · entry 8 El-Hibri Fuad · CIK 0001380185 · Director · Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,064 Underlying: Common Stock · 20,554 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · security: In connection with the Issuer's spin-off of Aptevo Therapeutics Inc. effective on August 1, 2016 (the "Spin-off"), the Issuer made certain adjustments to the price and number of equity awards held by the Issuer's continuing employees. Accordingly, Mr. El-Hibri received an equitable adjustment to the number and grant price of his restricted stock units. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F6 · derivative.exercise_date: On March 11, 2014, Mr. El-Hibri was granted 61,622 restricted stock units (after giving effect to the adjustment in connection with the Spin-off) vesting in three equal annual installments beginning on the day prior to the anniversary of the grant date. F6 · derivative.expiration_date: On March 11, 2014, Mr. El-Hibri was granted 61,622 restricted stock units (after giving effect to the adjustment in connection with the Spin-off) vesting in three equal annual installments beginning on the day prior to the anniversary of the grant date. Read SEC document |
| March 10, 2017 Filed Mar 10, 2017 22:48 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Tax withholdingCommon Stock | 6,089 | $31.05 | $189,063.45 |
DisclosureSEC source: 0000899243-17-007180 · doc4.xml · nonDerivative · entry 4 El-Hibri Fuad · CIK 0001380185 · Director · Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,680,216 Read SEC document |
| March 10, 2017 Filed Mar 10, 2017 22:48 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Exercise / conversionCommon Stock | 20,554 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-17-007180 · doc4.xml · nonDerivative · entry 3 El-Hibri Fuad · CIK 0001380185 · Director · Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,686,305 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| March 09, 2017 Filed Mar 10, 2017 22:48 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Exercise / conversionRestrictive Stock Units · Derivative | 13,236 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-007180 · doc4.xml · derivative · entry 7 El-Hibri Fuad · CIK 0001380185 · Director · Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,618 Underlying: Common Stock · 13,236 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · security: In connection with the Issuer's spin-off of Aptevo Therapeutics Inc. effective on August 1, 2016 (the "Spin-off"), the Issuer made certain adjustments to the price and number of equity awards held by the Issuer's continuing employees. Accordingly, Mr. El-Hibri received an equitable adjustment to the number and grant price of his restricted stock units. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F5 · derivative.exercise_date: On March 10, 2015, Mr. El-Hibri was granted 39,709 restricted stock units (after giving effect to the adjustment in connection with the Spin-off) vesting in three equal annual installments beginning on the day prior to the anniversary of the grant date. F5 · derivative.expiration_date: On March 10, 2015, Mr. El-Hibri was granted 39,709 restricted stock units (after giving effect to the adjustment in connection with the Spin-off) vesting in three equal annual installments beginning on the day prior to the anniversary of the grant date. Read SEC document |
| March 09, 2017 Filed Mar 10, 2017 22:48 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Tax withholdingCommon Stock | 3,621 | $30.98 | $112,178.58 |
DisclosureSEC source: 0000899243-17-007180 · doc4.xml · nonDerivative · entry 2 El-Hibri Fuad · CIK 0001380185 · Director · Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,665,751 Read SEC document |
| March 09, 2017 Filed Mar 10, 2017 22:48 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Exercise / conversionCommon Stock | 13,236 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-17-007180 · doc4.xml · nonDerivative · entry 1 El-Hibri Fuad · CIK 0001380185 · Director · Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,669,372 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| February 28, 2017 Filed Mar 3, 2017 01:58 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantEmployee Stock Option (right to buy) · Derivative | 58,747 | $0.00 Strike: $30.63 | $0.00 |
DisclosureSEC source: 0000899243-17-006216 · doc4.xml · derivative · entry 7 El-Hibri Fuad · CIK 0001380185 · Director · Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,747 Underlying: Common Stock · 58,747 shares Expires 2024-02-27 F7 · derivative.exercise_date: On February 28, 2017, Mr. El-Hibri was granted 58,747 stock options vesting in three equal annual installments beginning on the day prior to the anniversary of the grant date. Read SEC document |
| February 28, 2017 Filed Mar 3, 2017 01:58 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Exercise / conversionRestrictive Stock Units · Derivative | 9,722 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-006216 · doc4.xml · derivative · entry 6 El-Hibri Fuad · CIK 0001380185 · Director · Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,854 Underlying: Common Stock · 9,722 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · security: In connection with the Issuer's spin-off of Aptevo Therapeutics Inc. effective on August 1, 2016 (the "Spin-off"), the Issuer made certain adjustments to the price and number of equity awards held by continuing employees. Accordingly, Mr. El-Hibri, as a continuing Emergent employee with equity awards issued prior to the Spin-off, received an equitable adjustment to the number and grant price of his restricted stock units. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F6 · derivative.exercise_date: On March 1, 2016, Mr. El-Hibri was granted 29,167 restricted stock units (after giving effect to the adjustment in connection with the Spin-off) vesting in three equal annual installments beginning on the day prior to the anniversary of the grant date. F6 · derivative.expiration_date: On March 1, 2016, Mr. El-Hibri was granted 29,167 restricted stock units (after giving effect to the adjustment in connection with the Spin-off) vesting in three equal annual installments beginning on the day prior to the anniversary of the grant date. Read SEC document |
| February 28, 2017 Filed Mar 3, 2017 01:58 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantRestrictive Stock Units · Derivative | 29,382 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-006216 · doc4.xml · derivative · entry 5 El-Hibri Fuad · CIK 0001380185 · Director · Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,576 Underlying: Common Stock · 29,382 shares Expires not disclosed F4 · security: In connection with the Issuer's spin-off of Aptevo Therapeutics Inc. effective on August 1, 2016 (the "Spin-off"), the Issuer made certain adjustments to the price and number of equity awards held by continuing employees. Accordingly, Mr. El-Hibri, as a continuing Emergent employee with equity awards issued prior to the Spin-off, received an equitable adjustment to the number and grant price of his restricted stock units. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F5 · derivative.exercise_date: On February 28, 2017, Mr. El-Hibri was granted 29,382 restricted stock units vesting in three equal annual installments beginning on the day prior to the anniversary of the grant date. F5 · derivative.expiration_date: On February 28, 2017, Mr. El-Hibri was granted 29,382 restricted stock units vesting in three equal annual installments beginning on the day prior to the anniversary of the grant date. Read SEC document |
| February 28, 2017 Filed Mar 3, 2017 01:58 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Tax withholdingCommon Stock | 2,659 | $30.63 | $81,445.17 |
DisclosureSEC source: 0000899243-17-006216 · doc4.xml · nonDerivative · entry 2 El-Hibri Fuad · CIK 0001380185 · Director · Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,656,136 Read SEC document |
| February 28, 2017 Filed Mar 3, 2017 01:58 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Exercise / conversionCommon Stock | 9,722 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-17-006216 · doc4.xml · nonDerivative · entry 1 El-Hibri Fuad · CIK 0001380185 · Director · Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,658,795 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.